Investors Investors

Stock Quote

NASDAQ: PGNX
$10.36
+ 0.12
4:00 PM ET on February 24

Investor Relations

Progenics Investor relations Team works to provide, shareholders, analysts and potential investors with timely, relevant and reliable information.

We strive to make our press releases, scientific papers, and abstracts timely and accurate when issued. Subsequent events may affect their continued accuracy beyond the date of issuance and posting on the website. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties.

Presentations

Corporate Presentation

Offer to Purchase the shares of EXINI Diagnostics AB October 13, 2015

Progenics - Förlängd acceptperiod i Progenics erbjudande om förvärv av aktierna i EXINI avslutad

Progenics - Extended acceptance period in Progenics offer to acquire the shares in EXINI has ended

Progenics declares the offer for EXINI unconditional (Swedish language version)

Progenics declares the offer for EXINI unconditional (English language version)

Acceptance Form for Exini Shareholders

Progenics - Offer document (Swedish)

Progenics - Offer document (English)

Progenics - Offer announcement for release (Swedish)

Progenics - Offer announcement for release (English).pdf

EXINI - Press Release (Swedish)

EXINI - Press Release (English)

View all »   RSSRecent Releases

Feb 23, 2017
Progenics Pharmaceuticals Sets Fourth Quarter and Year-End 2016 Financial Results Call for March 9

Feb 14, 2017
Progenics Pharmaceuticals Announces Initiation of a Phase 1 Clinical Trial of its PSMA-Targeted Therapeutic Candidate 1095 For the Treatment of Metastatic Prostate Cancer

View all »Events & Presentations

Mar 9, 2017 at 8:30 AM ET
Progenics Pharmaceuticals Fourth Quarter 2016 Results Conference Call